3月6日 - ** 药物开发商ARS Pharmaceuticals SRY.O股价盘前上涨2.6%至11.15美元
** 该公司周三晚些时候表示， (link)，美国食品和药物管理局批准扩大鼻腔喷雾剂的使用范围，用于体重在15公斤至30公斤之间的严重过敏反应患者。
** 该喷雾剂以 neffy 品牌销售，新患者的剂量为 1 毫克。
** Neffy 设计用于在出现严重过敏反应的第一个迹象时使用，之前已获准用于体重超过 30 公斤的患者，剂量为 2 毫克。
** SPRY 在过去 12 个月中上涨了 21.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.